MAPT and Alzheimer disease: As an additional control method alternative to the use of soluble tau derived from human AD brain to further validate findings with recombinant oTau, we repeated the electrophysiological and behavioral studies in hTau mice naturally forming oTau from 6 months of age prior to NFT appearance and their control littermates lacking tau15.